Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A trial of Rigosertib for Pediatric RASopathies

Trial Profile

A trial of Rigosertib for Pediatric RASopathies

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Developmental disabilities
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Nov 2018 According to an Onconova Therapeutics media release, a clinical trial protocol concept has been developed and is under review. Based on NCI guidance, the Company expects the first patient to be treated in the first half of 2019.
    • 16 Nov 2017 New trial record
    • 09 Nov 2017 This trial is expected to start next year at National Cancer Institute and will be funded by the NIH, as reported in an Onconova Therapeutics media release.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top